In the face of COVID-19, the Brooke family got used to things being canceled: school and work now happen at their home. They were especially disappointed when 10-year-old Zoe’s second two-week visit to BRI, as part of a type 1 diabetes (T1D) study, had to be canceled.

Zoe is participating in the PROTECT study, which examines whether an immunotherapy drug can slow T1D down in patients who were recently diagnosed.

Some participants like Zoe were unable to receive their second set of infusions, as one of the many precautions taken to curb the spread of COVID-19, and the study has been postponed until trials can safely reopen.

But while her in-person visits were canceled, Zoe isn’t giving up. And BRI’s clinical research team is still supporting her and other participants from a distance until trials can safely reopen.

Learn more…